• Patients must be willing and able to sign the Informed Consent Form, and to adhere to the study visit schedule and other protocol requirements.

• Age ≥18 years (at the time consent is obtained).

• Patients with the following histologically confirmed, advanced cancer diagnoses:

‣ Serous, endometrioid, clear-cell, or mucinous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

⁃ Serous, endometrioid, or clear-cell endometrial cancer.

⁃ Adenocarcinoma of the lung.

⁃ Triple-negative breast cancer.

⁃ Pancreatic ductal adenocarcinoma.

⁃ Malignant pleural mesothelioma.

• Patients who have undergone any number of prior systemic therapies and have radiologically or clinically determined progressive disease during or after their most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.

• Patients must have at least one measurable or non-measurable lesion as per RECIST version 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate function of bone marrow, liver, kidneys, heart.

• Both male and female patients must agree to use effective contraceptive methods.

• Women of child-bearing potential (WCBP) must have a negative serum pregnancy test.

• Availability of tumour tissue sample (either an archival specimen or a fresh biopsy material) at screening.